Short answer
NovoCure Ltd (NVCR) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer.
NovoCure Ltd 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from non-small cell lung cancer
- Regulatory rejection reflects uncertainty over clinical benefit, not safety concerns
- Novocure plans FDA discussions on approval pathways without additional clinical studies
- Approval remains uncertain, creating commercialization and growth risk for the indication
Item EX-99.1 · Exhibit EX-99.1
- FDA Not Approvable Letter blocks Optune Mya approval for brain metastases from NSCLC after stereotactic radiation
- FDA cited uncertainty about clinical benefit, not safety concerns
- Novocure plans FDA discussions on approval pathways without additional clinical studies
- Approval remains uncertain, delaying potential expansion of Optune Mya’s addressable market
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NovoCure Ltd 8-K filings
Get the next NVCR 8-K as it lands
Follow NVCR for push alerts, or ask the research agent what this filing means.